InsightRX provides a cloud-based clinical decision support platform that applies quantitative pharmacology and artificial intelligence to enhance therapeutic decision-making from phase I drug development through individualized patient treatment at the point of care. The platform uses patient-specific data and quantitative models to tailor dosing for complex treatments, including antibiotics, chemotherapeutic agents, and immunosuppressants. InsightRX also employs AI to help data scientists analyze clinical-trial data, support trial design, clarify dose–exposure–response relationships, and refine dosing strategies for regulatory submissions. The company positions itself to move beyond a one-size-fits-all dosing paradigm toward individualized treatment for patient subgroups and individual patients. Leadership indicates the company will use external financing to accelerate growth and advance its strategic vision to transform patient care. InsightRX offers a precision dosing platform (Nova) and an integrated clinical analytics product (Apollo) that use patient demographics, physiology, genomics, drug concentrations and biomarkers to individualize medication dosing. The software integrates with EHRs such as Epic and Cerner and is embedded in clinical workflows to present dosing recommendations and simulations to clinicians. Its two-sided marketplace serves provider customers who buy drug modules (infectious disease, chemotherapy, immunology) and pharma/biotech clients that commission companion dosing applications for clinical trials and labels. The platforms are in use at more than a hundred healthcare institutions and life‑science organizations across the US and Europe. The company plans to deepen EHR integrations (including AllScripts and EDC systems for trials), expand into additional therapeutic areas (transplant, coagulation, IBD/Crohn’s, neutropenia) and add new product modules in infectious disease and oncology. InsightRX has raised venture funding (most recently a $10M Series A) and intends to use proceeds to accelerate integrations and product expansion. InsightRX is an early-stage San Francisco company that has developed a cloud-based precision medicine and clinical analytics platform. The platform leverages mathematical models, quantitative pharmacology, patient demographics, physiological characteristics, genomic data, drug concentrations and biomarkers to individualize drug selection and dosing. Its initial work has focused on chemotherapy drugs for children and certain complex antibiotics. The company aims to give clinicians and pharmacists tools to select the right drug and dose for the right patient, reducing adverse reactions and shortening hospital stays. Investors and partners describe the technology as having the potential to transform how drugs are administered worldwide and to enable targeted gene testing and co-development of dosing modules. InsightRX recently raised an early-stage financing led by Greatpoint Ventures Innovation Fund with participation from OSF Ventures.

Total raised

$10M

Funding rounds

3

Latest round

Series A

Latest activity

Sep 2019